GCIA
RVMD icon

Gabelli & Co Investment Advisers’s Revolution Medicines RVMD Stock Holding History

Gabelli & Co Investment Advisers’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$833K Sell
4,450
-8,950
-67% -$1.31M 0.12% 150
2026
Q1 		$1.3M Buy
+13,400
New +$1.35M 0.19% 100

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Gabelli & Co Investment Advisers's RVMD Position: Q2 2026 in Review

Gabelli & Co Investment Advisers reduced its Revolution Medicines (RVMD) stake by 67% in Q2 2026, selling an estimated $1.31M and leaving 4,450 shares worth $833K. The position accounts for 0.12% of the portfolio, ranked #150.

Gabelli & Co Investment Advisers first reported a position in RVMD in Q1 2026 and has held it in 2 quarters since. The position peaked at $1.3M in Q1 2026. 694 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • Gabelli & Co Investment Advisers held 4,450 shares of Revolution Medicines worth $833K as of Q2 2026.
  • Gabelli & Co Investment Advisers sold 8,950 Revolution Medicines shares in Q2 2026, an estimated $1.31M.
  • Revolution Medicines made up 0.12% of Gabelli & Co Investment Advisers's portfolio in Q2 2026, its #150 holding.
  • Gabelli & Co Investment Advisers first reported a position in Revolution Medicines in Q1 2026 and has held it in 2 quarters since.
  • Gabelli & Co Investment Advisers's Revolution Medicines position peaked at $1.3M in Q1 2026.
  • 694 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Gabelli & Co Investment Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.